Background And Objectives: To examine mammographic screening compliance among young military healthcare beneficiaries and to examine factors related to one time and recent mammographic compliance.

Methods: Medical records were reviewed for 1,073 subjects (age 41-47) recording dates of the two most recent screening mammograms. Examined outcomes were: whether the woman ever had mammography and, if so, whether she had a mammogram within 400 days. Examined predictors were: ethnicity, age, Gail Model risk score, family history, whether the woman knew a young woman with breast cancer, and importance attributed to breast cancer screening.

Results: 90.4% of women studied had at least one mammogram. 71.1% underwent screening within 400 days. Rates of ever having mammography were higher for women with family history of breast cancer and Asian, Pacific Islander, Black or Hispanic women. No measured covariate correlated with having mammography within 400 days.

Conclusions: One time screening participation was high in this select group of women for whom cost and access barriers were removed, but was lower with regard to having a recent mammogram. Correlates of ever having and recent mammography are not synonymous.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.20895DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
screening compliance
8
compliance young
8
400 days
8
family history
8
screening
5
women
5
breast
4
cancer screening
4
young women
4

Similar Publications

Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Beyond Boundaries in ERBB2-Positive Brain Metastatic Breast Cancer.

JAMA Netw Open

January 2025

Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.

View Article and Find Full Text PDF

Importance: Approximately one-third of patients with ERBB2 (formerly HER2 or HER2/neu)-positive (ERBB2+) metastatic breast cancer (MBC) develop brain metastasis. It is unclear whether patients with disease limited to the central nervous system (CNS) have different outcomes and causes of death compared with those with concomitant extracranial metastasis.

Objective: To assess overall survival (OS) and CNS-related mortality among patients with ERBB2+ breast cancer and a diagnosis of CNS disease by disease distribution (CNS only vs CNS plus extracranial metastasis).

View Article and Find Full Text PDF

Aims: We develop and evaluate copper-based metal-organic frameworks (Cu-MOFs) incorporating cromolyn as a linker to enhance structural stability, drug delivery efficiency, and therapeutic potential, particularly for breast cancer treatment.

Materials & Methods: Two Cu-MOF formulations were synthesized: Cu-MOFs-BDC-DOX (using terephthalic acid) and Cu-MOFs-CROMO-DOX (using cromolyn as a linker). Characterization was performed using SEM/TEM for morphology, and FTIR, XRD, and TGA to confirm structural integrity.

View Article and Find Full Text PDF

Aims And Objectives: Appropriately timed cessation of systemic anticancer treatments is an important part of a patient's quality of life (QoL). We aimed to determine the right time to discontinue systemic anticancer therapy (SACT) and switch to the best supportive care for patients with advanced breast cancer (BC) who are nearing the end of life.

Methods: We identified 200 BC patients who died within 30 days after palliative SACT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!